Product Program year 2025 Source: CMS Open Payments

Truvada

Drug Hiv

NDC 61958-0701-1

Open in the dashboard

General payments

$1,452,613

3,174 payments

Research payments

$4,677,703

102 payments

Through program year 2025, $1,452,613 in general payments and $4,677,703 in research payments were reported against Truvada (Hiv).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

10 rows
Year Kind Amount Payments
2025 Research $259,254 3
2024 Research $11,345 2
2023 Research $262,751 10
2022 Research $657,582 12
2021 General $1,379 3
2021 Research $1,098,417 20
2020 General $1,730 1
2020 Research $836,419 22
2019 General $1,449,505 3,170
2019 Research $1,551,935 33

Breakdown

Who paid General payments · program years 2019–2021
  1. Gilead Sciences, Inc. $1,452,613 3,174 payments
Top recipients General payments · program year 2021
  1. John Phoenix Nurse Practitioner, Family · Las Vegas, NV $1,360 99% · 2 payments
  2. Roberta Laguerre Pediatrics · Philadelphia, PA $19 1% · 1 payment

Each share is of general payments naming this product in 2021.

Specialties paid General payments · program year 2021
  1. Nurse Practitioner, Family Nurse Practitioner $1,360 99% · 1 practitioner
  2. Pediatrics $19 1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Nevada $1,360 99% · 1 recipient
  2. Pennsylvania $19 1% · 1 recipient

Each share is of general payments naming this product in 2021 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

791

Prescriptions dispensed, refills included

Drug cost

$1,373,483

Paid at the pharmacy, in all

Prescribers

49

With 11 or more claims of it

Medicare Part D drugs matched to Truvada, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Truvada Emtricitabine/Tenofovir (Tdf) Same name 49 791 $1,373,483

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 49 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Alade Afolabi Nurse Practitioner FL 94 $155,580 None on record
Lashena Jackson Nurse Practitioner FL 42 $78,635 None on record
Bianca Bachoo Nurse Practitioner FL 40 $68,698 None on record
Jorge Brito Nurse Practitioner FL 26 $44,035 None on record
Nadeem Khan Infectious Disease FL 23 $41,451 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 49 with Patron
3,174 general · 102 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record